FoldRx banks $29M for neurodegenerative drug application

Cambridge, MA-based FoldRx has rounded up $29 million in new funding, with new investors Novo Ventures and Morgenthaler Ventures joining Healthcare Ventures, Fidelity Biosciences, TPG Biotechnology, Alta Partners, and Novartis Venture Funds to back the developer. The money will be used to fund the advancement of tafamidis, a new neurodegenerative disease therapy, through a marketing application later this year as well as a commercial launch. "This financing is recognition of the...